Resources
Get helpful information about MRD and M-inSight®
All
Articles
Documentation
Events
Posters
Publications
M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator - CCLM 2024
Monitoring of Systemic Light-Chain Amyloidosis patients using Mass Spectrometry (M-inSight) in serum - ASH 2023
Multiple Myeloma MRD tracking in blood using ultra sensitive Mass Spectrometry (M-inSight) - ASH 2023
Personalized mass spectrometry as a tool for minimal residual disease detection in the blood of myeloma patients - IMS 2023
Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma - Cancers 2021
Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma - Blood Adv. 2020
Development of a Targeted MS Serum Assay To Quantify M‑Protein in the Presence of Therapeutic Monoclonal Antibodies - J Proteome Res. 2018
Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for MRD Monitoring in MM - Clin Chem. 2021
